Revolution Medicines, Inc. (RVMD)

Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline consist of RAS(ON) inhibitors that binds RAS variants to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors to suppress cooperating targets and pathways that sustain RAS-addicted cancers. Its RAS(ON) inhibitors include daraxonrasib (RMC-6236), elironrasib G12C (RMC-6291) which is in early clinical development for the treatment of solid tumors, and zoldonrasib G12D (RMC-9805), which are in phase 3 registrational trial evaluating the combination of daraxonrasib with zoldonrasib in patients with 1L PDAC; and development candidates comprise RMC-5127 (G12V) which is in clinical trial, RMC-0708 (Q61H), that is in clinical trial; and RMC-8839 (G13C). Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.

• 年度报告（10-K）

  对公司业务、财务业绩和风险的年度概述。

  提交日期：2026-02-25

  查看文件

• 季度报告（10-Q）

  最近三个月财务表现的最新情况。

  提交日期：2026-08-05

  查看文件

• 临时报告（8-K）

  关于重大事件（如管理层变动或重要公告）的通知。

  提交日期：2026-09-01

  查看文件

• 8/27/2026POSITIVE
  RevMed’s Pancreatic Cancer Pill Priced Above $475K per Year

  Revolution Medicines has secured US approval for Rasonque, a novel pill targeting advanced pancreatic cancer, a significant breakthrough in treating a notoriously difficult tumor type. The drug, priced at over $475,000 annually, is among the most expensive cancer therapies developed. Its broad targeting of the RAS protein, a key driver in most pancreatic cancers, offers a new therapeutic avenue. This approval marks a substantial advancement in oncology, potentially improving patient outcomes and establishing a new standard of care for this challenging disease.

• 6/1/2026POSITIVE
  Revolution Medicines' Pancreatic Cancer Pill Doubles Survival, Cuts Death Risk 60% in Trial As Stock Sits Near All-Time Highs

  Revolution Medicines announced a significant breakthrough in pancreatic cancer treatment, with its experimental pill demonstrating a doubling of patient survival rates and a 60% reduction in the risk of death during clinical trials. This development is particularly noteworthy given the historically poor prognosis associated with pancreatic cancer. The positive trial results suggest a potential paradigm shift in treatment options for this aggressive disease. For investors, this news could translate into substantial future revenue streams and a re-evaluation of the company's growth prospects, especially as the stock is currently trading near its all-time highs.

• 4/13/2026POSITIVE
  Revolution Medicines Rallies After Phase 3 Pancreatic Cancer Trial Doubles Survival Versus Chemo

  Revolution Medicines Inc. stock surged following promising Phase 3 trial results for its pancreatic cancer drug, darsonvalrasib. The study demonstrated a doubling of survival rates compared to standard chemotherapy, a significant breakthrough for patients with KRAS G12C-mutated pancreatic cancer. The company announced plans for regulatory filings, signaling a clear path toward potential market approval. This development is highly encouraging for investors, suggesting a strong future revenue stream and a significant advancement in oncology treatment.

• 2/25/2026NEUTRAL
  Revolution Medicines (RVMD) Earnings Transcript

  Revolution Medicines (RVMD) has released its earnings transcript, although the specific content is not yet available for analysis. Investors are keenly awaiting the details of this publication, which could provide clarity on the company's financial performance and future outlook. The absence of immediate information prevents a directional assessment, keeping the stock in a holding pattern. It will be crucial to monitor the data as soon as it is disclosed to understand the impact on research and development, product pipeline, and market strategies, which are fundamental elements for evaluating RVMD's growth potential in the biopharmaceutical sector.